Reuters logo
BRIEF-AstraZeneca sells rights for beat-blocker Seloken to Recordati
May 22, 2017 / 6:20 AM / 7 months ago

BRIEF-AstraZeneca sells rights for beat-blocker Seloken to Recordati

May 22 (Reuters) - AstraZeneca Plc

* Astrazeneca enters agreement with Recordati for seloken in europe

* Expands commercial potential of seloken in european markets

* Recordati will pay astrazeneca $300 million upon completion of agreement Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below